Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Informa reports solid year as it pivots to more profitable markets

(Sharecast News) - Informa reported a solid set of financial results for 2024 on Thursday, delivering double-digit revenue and profit growth alongside record free cash flow. The FTSE 100 events and business information company said revenue rose 11.4% to £3.55bn, with adjusted operating profit increasing 16.5% to £995m.

Free cash flow grew 28.6% to £812m, supported by strong operational performance and disciplined cash management.

Adjusted diluted earnings per share increased 10.6% to 50.1p, while statutory operating profit rose 6.9% to £542.8m.

The company said it continued its international expansion through the year, shifting its B2B focus towards faster-growing markets in the Americas, the GCC and Asia, which now accounted for around 85% of group revenue.

Informa announced a strategic partnership with Dubai World Trade Centre, creating a joint venture, Informa International, that would consolidate B2B events in the UAE and surrounding markets.

Expected to complete in late 2025, the venture was set to generate over $700m in revenue with operating margins above 30%, adding scale in key growth sectors such as healthcare, aviation, and information security.

Informa reaffirmed strong momentum heading into 2025, with over £1.7bn in revenue already booked, committed or paid.

The company said it was targeting full-year revenue of more than £4.1bn, excluding divested businesses, and expected double-digit earnings growth.

It said its four-year 'One Informa' strategy would focus on expanding its brand portfolio, enhancing customer experience, and deploying AI-driven digital services.

The company maintained its commitment to shareholder returns, increasing its total dividend for the year by 11.1% to 20p per share and executing £425m in share buybacks, bringing total cash returns to £675m.

Informa said it would restart share repurchases in 2025 with an initial commitment of at least £200m.

It ended the year with a net debt-to-adjusted EBITDA ratio of 2.6x, with further deleveraging expected.

The company also advanced its sustainability initiatives, achieving recognition in the Dow Jones Sustainability Index for the seventh consecutive year and maintaining top-tier ESG ratings from MSCI and CDP.

Looking ahead, the firm said it was focussed on structural growth opportunities and further international expansion to drive long-term profitability.

"On every measure, the Informa group delivered an outstanding result in 2024, from revenue growth to higher dividend returns, alongside further International and portfolio expansion - this is a performance we aim to repeat in 2025," said group chief executive officer Stephen Carter.

"Our growth ambitions through the 2025-2028 One Informa period are underpinned by structural growth in B2B events and specialist knowledge, market-leading brands and a geographic mix weighted to fast-growing economies.

"Further scale and opportunity in the increasingly important GCC Growth Gateway is delivered through today's proposed strategic partnership in the UAE."

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.